that cause significant mortality and
morbidity in Africa are treatable or
manageable with existing drugs. What
stands in the way of treatment, and hence
survival, is access to affordable drugs.
Our focus is on producing effective and
affordable medicines for the treatment of
diseases endemic to sub-Saharan Africa and
for improving the quality of life in Africa.
produce drugs for the treatment of
infectious diseases such as HIV/AIDS and its
associated opportunistic infections,
respiratory tract infections, malaria and other
parasitic infections, fungal infections and
also developing a portfolio of drugs for the
management of key non-communicable diseases
such as hypertension and diabetes.
LaGray is the first manufacturer of APIs
in West Africa and the first fully
self-sufficient pharmaceutical manufacturer
in the region.
facility is designed and built in accordance
with current international standards of good manufacturing practices for
pharmaceuticals. We operate in strict
adherence to the principles of cGMP.